Background. This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries.
INTRODUCTION
The European Renal Association -European Dialysis and Transplant Association (ERA-EDTA) Registry's Annual Report describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) within Europe and countries bordering the Mediterranean Sea, based on the data collected via national and regional renal registries [1] . The summary of the ERA-EDTA Registry Annual Report, which is published on an annual basis, is intended to provide an overview of the current status of RRT for ESRD in Europe [2] [3] [4] . In 2017 and 2018, data for the year 2016 were received from 52 national or regional renal registries in 36 countries covering a general population of 686.9 million people. When leaving out Israel and Tunisia, the remaining countries cover a general population of 677.3 million people, representing 80.5% of the 2016 European general population, which was similar to 2015 (80.3%). A total of 32 national or regional renal registries from 17 countries provided individual patient data, whereas 20 countries or regions provided aggregated data (see Appendix A1). Compared to the 2015 ERA-EDTA Registry Annual Report, there were no differences in country participation. This summary presents the 2016 incidence and prevalence of RRT, kidney transplantation activity, and the patient and graft survival. A description of the methods used to analyse the data, along with the full results, can be found in the ERA-EDTA Registry 2016 Annual Report [1] .
On the occasion of the 2018 global focus on kidneys and women's health, this year's annual report contains additional analyses on sex comparisons, a summary of which is also presented in this article.
RESULTS

Incidence of RRT
In 2016, 83 311 individuals commenced RRT for ESRD, which equated to an overall unadjusted incidence of 121 per million population (pmp; Table 1 ). The unadjusted incidence was highest in Greece (251 pmp), Czech Republic (243 pmp) and Portugal (236 pmp), whereas it was lowest in Ukraine (29 pmp) and Russia (59 pmp; Table 1 and Figures 1 and 2 ). Of the patients commencing RRT, 62% were men, 52% were aged 65 years and 23% had diabetes mellitus (DM) as their primary renal diagnosis ( Figure 3 ). The median age of the patients commencing RRT in all countries and regions combined was 65.8 years, ranging from 51.0 years in Ukraine to 73.8years in the Dutch-speaking part of Belgium (Table 1) . The majority of patients started RRT with haemodialysis (HD; 84%), while 12% of patients started with peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant (Figure 4 ). However, the initial treatment modality varied considerably between age groups, as the proportion of patients receiving either PD or a pre-emptive transplant decreased with increasing age. Furthermore, patients with a primary renal diagnosis of DM were less likely to receive a pre-emptive kidney transplant compared with non-diabetic patients (2% versus 6%). Of the incident patients receiving RRT at Day 91 after the start of treatment, the majority (82%) were receiving HD, 13% were receiving PD and 5% were living with a kidney transplant ( Figure 5 ). In the first 90 days of treatment, the percentage of patients receiving HD decreased, and this was particularly evident in the younger age groups.
Prevalence of RRT
On 31 December 2016, 564 638 individuals were receiving RRT for ESRD (Table 2) , corresponding to an overall unadjusted prevalence of 823 pmp. Again, there was considerable variation between countries, with the highest unadjusted prevalence seen in Portugal (1906 pmp) and the Spanish regions of Catalonia (1399 pmp) and Valencia (1388 pmp; Table 2 and Figures 6 and 7) . The unadjusted prevalence of RRT was considerably lower in Ukraine (188 pmp) and Belarus (289 pmp). The top five countries with the highest prevalence of RRT have remained the same since 2014. Of the prevalent patients, 60% were men, 42% were aged 65 years and 17% had DM as their primary renal diagnosis ( Figure 8 ). The median age of prevalent patients receiving RRT in all countries and regions combined was 62.4 years, ranging from 50.7 years in Albania to 68.0 years in Israel ( Table 2 ). The majority of prevalent patients (58%) were receiving HD, 37% of patients were living with a kidney transplant and only 5% were receiving PD ( Figure 9 ). Once again the modality of RRT varied considerably between age groups as the proportion of patients with a kidney transplant decreased with increasing age. For those aged 20-44 years, 66% were living with a kidney transplant, whereas this was only 42% for patients aged 65-74 years. Prevalent patients with a primary renal diagnosis of DM were much less likely to be living with a kidney transplant compared with the patients without DM (28% versus 50%).
Kidney transplantation
In 2016, 22 046 kidney transplantations were performed, which equated to an overall unadjusted transplant rate of 32 pmp ( Figure 10 ). Again there was considerable variation between countries/regions with unadjusted kidney transplant rates well over 70 pmp in several Spanish regions, and very low unadjusted kidney transplant rates in Ukraine (3 pmp) and Macedonia (3 pmp) . Overall, the unadjusted deceased donor kidney transplant rate was more than twice that of the unadjusted living donor transplant rate (22 pmp versus 9 pmp; 70% versus 30%; Figure 11 ). The highest unadjusted rates of deceased donor kidney transplants were seen in some Spanish regions (>70 pmp; Figure 12 ), whereas the highest unadjusted rate of living donor transplants was seen in Northern Ireland (38 pmp), the Netherlands (33 pmp) and Turkey (33 pmp; Figure 12 ).
Survival of patients receiving RRT
For patients commencing RRT in the period 2007-11, the 5-year unadjusted patient survival probability for all RRT modalities combined was 50.5% [95% confidence interval (CI) 50. 4-50.6 ]. For patients commencing RRT with dialysis between 2007 and 2011, the 5-year unadjusted patient survival probability was 42.1% (95% CI 42.0-42.3). Adjusted analyses for patient survival on HD and PD revealed higher survival probabilities in the first 3 years for patients receiving PD ( Figure 13 ). For those with a kidney transplant, 5-year adjusted patient and graft survival were higher for living donor transplants compared with deceased donor transplants: 94.6% (95% CI 94.1-95.1) versus 91.9% (95% CI 91.6-92.3) for patient survival and 86.7% (95% CI 85.9-87.4) versus 80.9% (95% CI 80. 4-81.4) for graft survival. See Table 3 for a description of the adjustments made and the countries/regions included in these analyses.
Expected remaining lifetime
There is still a substantial difference in the expected remaining lifetime between the general population and those receiving dialysis ( Figure 14 ). Patients aged 20-44 years receiving dialysis Data on incidence of primary renal disease (DM) is based on 2078 dialysis patients (18.6% of total). e The incidence is underestimated by 2% due to a small number of centres not submitting complete data for 2016. DM, diabetes mellitus as primary renal disease.
FIGURE 1: Incidence of RRT pmp in 2016, at Day 1, by country/region, unadjusted. The incidence for Czech Republic, Poland, Russia, Slovakia and Tunisia (Sfax region) only includes patients receiving dialysis. For Serbia and England (UK), the incidence is underestimated by, respectively, 26% and 2% (see Table 1 ). shown as dark bars, and registries providing aggregated data as light bars. Adjustment of incidence was performed by standardizing the rates to the age and gender distribution of the EU27 population [5] . The incidence for Czech Republic, Poland, Russia, Slovakia and Tunisia (Sfax region) only includes patients receiving dialysis. For Serbia and England (UK), the incidence is underestimated by, respectively, 26% and 2% (see Table 1 ). are expected to live only one-third of the expected remaining lifetime of the age-matched general population, which is about 33 years less. The prospect is even worse for patients aged 45-64 years, as they are expected to live only a quarter as long as their age-matched counterparts in the general population (21 years less). Patients living with a kidney transplant fare better than those receiving dialysis. However, the life expectancy of the transplant recipients aged 20-44 years is still 30% less than that of the age-matched general population (15 years less). Thus, as the age of the transplant recipient increases, the relative difference in the expected remaining lifetime from that of the age-matched general population also increases although the absolute difference decreases.
Sex comparisons
Figures 15-31 showing comparisons of the sexes are based on the data from 32 national or regional renal registries from 17 countries that provided individual patient data, representing 33.8% of the 2016 European general population.
In 2016, 26 446 men and 14 820 women commenced RRT resulting in a higher unadjusted incidence among men (187 pmp) than women (101 pmp). This was the case for all age groups, with the incidence in men aged 75 years (807 pmp) being 2.7 times that of women aged 75 years (300 pmp; Figure 15 ). In men and women commencing RRT, the distribution of the age groups was very similar (Figure 16 ). About 36% of patients commencing RRT were female, decreasing from around 39% of patients <45 years at the start of RRT to about 36% of patients aged 45 years ( Figure 17) .
Diabetes was the most frequent primary renal disease in both men and women starting RRT ( Figure 18 ). The incidence of men starting RRT for ESRD due to glomerulonephritis/sclerosis (23 pmp) and hypertension (29 pmp) was more than double that of their female counterparts (10 and 13 pmp, respectively), while the incidence of polycystic kidney disease in men (9 pmp) was only about 30% higher than in women (7 pmp). When viewed by sex, the distribution of the primary renal disease was similar. Of the men commencing RRT, 16% had hypertension and 12% had glomerulonephritis/sclerosis, and for women this was 13 and 10%, respectively (Figure 19) .
The incidence of all treatment modalities was higher among men than women (Figure 20) . Of the men and women initiating RRT in 2016, the majority started with HD (82 and 81%, respectively; Figure 21 ). Although more men (8 pmp) than women (5 pmp) received a pre-emptive transplant, the percentage of patients starting RRT with a pre-emptive transplant was similar among men (4%) and women (5%).
On 31 December 2016, 195 810 men and 121 755 women were receiving RRT for ESRD, resulting in a higher prevalence of RRT among men (1381 pmp) than women (827 pmp), which was the case for all age groups (Figure 22 ). In men, the highest prevalence was found in the group aged 75 years, whereas in women the highest prevalence was found in the group aged 65-74 years. The age distribution of patients receiving RRT was similar for both sexes, with most patients in the 45-to 64-year age group (39%; Figure 23 ). The percentage of women within the different age groups varied between 37% among patients aged 65-74 years and 40% among patients aged 0-19 years (Figure 24) . The prevalence of men on RRT with glomerulonephritis/sclerosis and hypertension (301 and 167 pmp) was more than twice that of women (140 and 75 pmp; Figure 25 ). For men receiving RRT, the most frequent primary renal disease was glomerulonephritis/sclerosis (22%), while for women their most frequent primary renal disease category was 'miscellaneous' (Figure 26 , Appendix 2). For both men and women, the majority of patients were receiving HD (668 and 399 pmp), and slightly fewer men and women were living with a kidney transplant (642 and 382 pmp, respectively; Figure 27 ). The distribution of treatment modalities was similar across the sexes (Figure 28) .
In 2016, 8355 kidney transplantations were performed in men, and 4827 in women, equating to transplant rates of 59 and 33 pmp, respectively (Figure 29 ). For men, 22% of the transplants came from living donors, and for women 24% (Figure 30 ).
For patients commencing RRT with dialysis in the period 2007-11, for both HD and PD, the adjusted patient survival probabilities were higher for women than for men ( Figure 31 ). For both men and women receiving a kidney transplant in the period 2007-11, the adjusted patient survival was higher with a living donor transplant compared with a deceased donor transplant, and this difference was more prominent in men than in women. The prevalence is underestimated by 29% due to centres not submitting complete data for 2016. e The prevalence is underestimated by 6% due to an estimated 11% under-reporting of patients living with a functioning graft. f Data on the prevalence of primary renal disease (DM) is based on 8043 dialysis patients (10.8% of total) g The prevalence is underestimated by 1% due to a small number of centres not submitting complete data for 2016. Switzerland and England (UK), the prevalence is underestimated by, respectively, 30, 29, 6 and 1% (see Table 2 ). ERA-EDTA Registry Annual Report 2016 | 711 data are shown as dark bars, and registries providing aggregated data as light bars. Adjustment of the prevalence was performed by standardizing the prevalence to the age and gender distribution of the EU27 population [5] . The prevalence for Israel only includes patients receiving dialysis. For Romania, Serbia, Switzerland and England (UK), the prevalence is underestimated by, respectively, 30, 29, 6 and 1% (see Table 2 
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